Inflammation is frequently associated with human benign prostatic hyperplasia (BPH) and may concur in the development of urinary obstruction.Cyclooxygenase-2 (COX-2) is an inducible pro-inflammatory enzyme. COX-2 is expressed in prostate tissue, including BPH, and it may stimulate prostate growth by its ability to increase prostaglandin synthesis, promote angiogenesis and inhibit apoptosis. The aim of the study was to analyze whether combination therapy with rofecoxib, a COX-2 inhibitor, and finasteride, an inhibitor of prostatic 5alfa-reductase, offers an advantage compared to finasteride monotherapy in patients with symptomatic BPH.
Finasteride and rofecoxib combination in the treatment of benign prostatic hyperplasia (BPH) / PROIETTI PANNUNZI, Laura; DI SILVERIO, Franco; Sciarra, Alessandro; Lolli, Francesca; TOSTI CROCE, Carlo; M., Poggi; Toscano, Vincenzo; S., Monti. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 1720-8386. - STAMPA. - 28:(2005), p. 18. (Intervento presentato al convegno XXXI Congresso Nazionale della Società Italiana di Endocrinologia tenutosi a Genova nel 4-7 Maggio 2005).
Finasteride and rofecoxib combination in the treatment of benign prostatic hyperplasia (BPH)
PROIETTI PANNUNZI, LAURA;DI SILVERIO, Franco;SCIARRA, Alessandro;LOLLI, FRANCESCA;TOSTI CROCE, Carlo;TOSCANO, Vincenzo;
2005
Abstract
Inflammation is frequently associated with human benign prostatic hyperplasia (BPH) and may concur in the development of urinary obstruction.Cyclooxygenase-2 (COX-2) is an inducible pro-inflammatory enzyme. COX-2 is expressed in prostate tissue, including BPH, and it may stimulate prostate growth by its ability to increase prostaglandin synthesis, promote angiogenesis and inhibit apoptosis. The aim of the study was to analyze whether combination therapy with rofecoxib, a COX-2 inhibitor, and finasteride, an inhibitor of prostatic 5alfa-reductase, offers an advantage compared to finasteride monotherapy in patients with symptomatic BPH.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
